-
1
-
-
84941188644
-
-
Titusville, NJ: Janssen Pharmaceuticals, Inc.
-
Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2015.
-
(2015)
Xarelto [Package Insert]
-
-
-
2
-
-
79951784125
-
Evaluations of drug-induced serious hepatotoxicity (eDISH): Application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery
-
Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluations of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34:243-252.
-
(2011)
Drug Saf
, vol.34
, pp. 243-252
-
-
Watkins, P.B.1
Desai, M.2
Berkowitz, S.D.3
Peters, G.4
Horsmans, Y.5
Larrey, D.6
-
3
-
-
84896544335
-
Risk of drug-induced liver injury with the new oral anticoagulants: Systematic review and meta-analysis
-
Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira J, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014; 100:550-556.
-
(2014)
Heart
, vol.100
, pp. 550-556
-
-
Caldeira, D.1
Barra, M.2
Santos, A.T.3
De Abreu, D.4
Pinto, F.J.5
Ferreira, J.6
-
4
-
-
33744506277
-
Drug-induced liver injury: Hy's rule revisited
-
Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79:521-528.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 521-528
-
-
Bjornsson, E.1
-
5
-
-
84901824190
-
An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data
-
Cheetham TC, Lee J, Hunt CM, Niu F, Reisinger S, Murray R, et al. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol Drug Saf 2014; 23:601-608.
-
(2014)
Pharmacoepidemiol Drug Saf
, vol.23
, pp. 601-608
-
-
Cheetham, T.C.1
Lee, J.2
Hunt, C.M.3
Niu, F.4
Reisinger, S.5
Murray, R.6
-
6
-
-
84904725750
-
Rivaroxaban postmarketing risk of liver injury
-
Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hurlimann S, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014; 61:293-300.
-
(2014)
J Hepatol
, vol.61
, pp. 293-300
-
-
Russmann, S.1
Niedrig, D.F.2
Budmiger, M.3
Schmidt, C.4
Stieger, B.5
Hurlimann, S.6
-
7
-
-
6444234849
-
There Is No Evidence for an Increase in Acute Coronary Syndromes after Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients
-
McGowan MP. There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients. Circulation 2004; 110:2333-2335.
-
(2004)
Circulation
, vol.110
, pp. 2333-2335
-
-
McGowan, M.P.1
-
8
-
-
0027362542
-
Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meeting: Application to drug-induced liver injuries
-
Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meeting: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
-
(1993)
J Clin Epidemiol
, vol.46
, pp. 1323-1330
-
-
Danan, G.1
Benichou, C.2
-
9
-
-
84907964271
-
Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban
-
Liakoni E, Ratz BravoAE, Terracciano L, HeimM, Krahenbuhl S.Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 2014; 174:1683-1686.
-
(2014)
JAMA Intern Med
, vol.174
, pp. 1683-1686
-
-
Liakoni, E.1
Ratz Bravo, A.E.2
Terracciano, L.3
Heim, M.4
Krahenbuhl, S.5
-
10
-
-
84930384694
-
Severe drug-induced skin and liver injury from rivaroxaban
-
Epub ahead of print
-
Barrett P, Vuppalanchi R, Masuoka H, Chalamsani N. Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci 2015; Epub ahead of print; doi: 10.1007/s10620-014-3504-9.
-
(2015)
Dig Dis Sci
-
-
Barrett, P.1
Vuppalanchi, R.2
Masuoka, H.3
Chalamsani, N.4
-
11
-
-
33646198164
-
Anticoagulants and transaminase elevations
-
Arora N, Goldhaber SZ. Anticoagulants and transaminase elevations. Circulation 2006; 113:e698-e702.
-
(2006)
Circulation
, vol.113
, pp. e698-e702
-
-
Arora, N.1
Goldhaber, S.Z.2
-
12
-
-
8844255607
-
-
Princeton, NJ: Bristol-Myers Squibb Company
-
Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
-
(2011)
Coumadin [Package Insert]
-
-
-
13
-
-
84930923588
-
-
Princeton, NJ: Bristol-Myers Squibb Company
-
Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
-
(2014)
Eliquis [Package Insert]
-
-
-
14
-
-
84942658256
-
-
U.S. National Library of Medicine. Accessed Jan
-
National Institute of Diabetes and Digestive and Kidney Diseases. 'Spironolactone' LiverTox. U.S. National Library of Medicine. Accessed Jan. 2015. http://livertox.nih.gov/Spironolactone.htm.
-
(2015)
Spironolactone LiverTox
-
-
-
16
-
-
84877301336
-
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation
-
Heiduchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013; 15:625-651.
-
(2013)
Europace
, vol.15
, pp. 625-651
-
-
Heiduchel, H.1
Verhamme, P.2
Alings, M.3
Antz, M.4
Hacke, W.5
Oldgren, J.6
|